{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:44:34Z","timestamp":1790876674967,"version":"4.1.0"},"reference-count":90,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Canadian Institutes of Health Research (CIHR) First Pilot Foundation","award":["143348"],"award-info":[{"award-number":["143348"]}]},{"name":"Canada Research Chair (CRC) on Hypertension and Vascular Research by the CRC Government of Canada\/CIHR Program"},{"name":"Canada Fund for Innovation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Current knowledge suggests that hypertension is in part mediated by immune mechanisms. Both interleukin (IL)-23 and IL-17 are up-regulated in several experimental hypertensive rodent models, as well as in hypertensive humans in observational studies. Recent preclinical studies have shown that either IL-23 or IL-17A treatment induce blood pressure elevation. However, the IL-23\/IL-17 axis has not been a major therapeutic target in hypertension, unlike in other autoimmune diseases. In this review, we summarize current knowledge on the role of these cytokines in immune mechanisms contributing to hypertension, and discuss the potential of IL-23\/IL-17-targeted therapy for treatment of hypertension.<\/jats:p>","DOI":"10.1093\/cvr\/cvaa257","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T15:12:08Z","timestamp":1598368328000},"page":"1274-1283","source":"Crossref","is-referenced-by-count":41,"title":["Role of interleukin-23\/interleukin-17 axis in T-cell-mediated actions in hypertension"],"prefix":"10.1093","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0827-874X","authenticated-orcid":false,"given":"Akinori","family":"Higaki","sequence":"first","affiliation":[{"name":"Lady Davis Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8873-9245","authenticated-orcid":false,"given":"Ahmad U M","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Lady Davis Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5692-1891","authenticated-orcid":false,"given":"Pierre","family":"Paradis","sequence":"additional","affiliation":[{"name":"Lady Davis Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4502-2823","authenticated-orcid":false,"given":"Ernesto L","family":"Schiffrin","sequence":"additional","affiliation":[{"name":"Lady Davis Institute for Medical Research"},{"name":"Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, 3755 C\u00f4te-Ste-Catherine Road, Montreal, Quebec H3T 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"2021042318143730000_cvaa257-B1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1084\/jem.20171773","article-title":"The immunology of hypertension","volume":"215","author":"Norlander","year":"2018","journal-title":"J Exp Med"},{"key":"2021042318143730000_cvaa257-B2","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/bph.14427","article-title":"Role of immune cells in hypertension","volume":"176","author":"Caillon","year":"2019","journal-title":"Br J Pharmacol"},{"key":"2021042318143730000_cvaa257-B3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"2021042318143730000_cvaa257-B4","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J Biol Chem"},{"key":"2021042318143730000_cvaa257-B5","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"2021042318143730000_cvaa257-B6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ni.3579","article-title":"Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease","volume":"18","author":"Pfeifle","year":"2017","journal-title":"Nat Immunol"},{"key":"2021042318143730000_cvaa257-B7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/HJH.0b013e32835bcce1","article-title":"The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Hypertens"},{"key":"2021042318143730000_cvaa257-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/3159283","article-title":"Arterial hypertension and interleukins: potential therapeutic target or future diagnostic marker?","volume":"2019","author":"Tanase","year":"2019","journal-title":"Int J Hypertens"},{"key":"2021042318143730000_cvaa257-B9","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/HYPERTENSIONAHA.112.199265","article-title":"Interferon-gamma signaling inhibition ameliorates angiotensin II-induced cardiac damage","volume":"60","author":"Marko","year":"2012","journal-title":"Hypertension"},{"key":"2021042318143730000_cvaa257-B10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1159\/000343327","article-title":"Angiotensin II induces TSLP via an AT1 receptor\/NF-KappaB pathway, promoting Th17 differentiation","volume":"30","author":"Zhao","year":"2012","journal-title":"Cell Physiol Biochem"},{"key":"2021042318143730000_cvaa257-B11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.atherosclerosis.2013.12.004","article-title":"Treatment with telmisartan\/rosuvastatin combination has a beneficial synergistic effect on ameliorating Th17\/Treg functional imbalance in hypertensive patients with carotid atherosclerosis","volume":"233","author":"Liu","year":"2014","journal-title":"Atherosclerosis"},{"key":"2021042318143730000_cvaa257-B12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/HYPERTENSIONAHA.113.02620","article-title":"Deficiency of the interleukin 17\/23 axis accelerates renal injury in mice with deoxycorticosterone acetate+angiotensin II-induced hypertension","volume":"63","author":"Krebs","year":"2014","journal-title":"Hypertension"},{"key":"2021042318143730000_cvaa257-B13","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1172\/JCI74084","article-title":"DC isoketal-modified proteins activate T cells and promote hypertension","volume":"124","author":"Kirabo","year":"2014","journal-title":"J Clin Invest"},{"key":"2021042318143730000_cvaa257-B14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.trsl.2014.11.007","article-title":"Effects of dietary salt levels on monocytic cells and immune responses in healthy human subjects: a longitudinal study","volume":"166","author":"Yi","year":"2015","journal-title":"Transl Res"},{"key":"2021042318143730000_cvaa257-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/6904325","article-title":"the role of interleukin-17, interleukin-23, and transforming growth factor-beta in pregnancy complicated by placental insufficiency","volume":"2017","author":"Darmochwal-Kolarz","year":"2017","journal-title":"Biomed Res Int"},{"key":"2021042318143730000_cvaa257-B16","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3389\/fphys.2018.01581","article-title":"SGK1-FoxO1 signaling pathway mediates Th17\/Treg imbalance and target organ inflammation in angiotensin II-induced hypertension","volume":"9","author":"Du","year":"2018","journal-title":"Front Physiol"},{"key":"2021042318143730000_cvaa257-B17","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.044107","article-title":"Activated pathogenic Th17 lymphocytes induce hypertension following high-fructose intake in Dahl salt-sensitive (SS) but not Dahl salt-resistant (SR) rats","author":"Lee","year":"2020","journal-title":"Dis Model Mech"},{"key":"2021042318143730000_cvaa257-B18","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3389\/fimmu.2018.01323","article-title":"The interleukin-23\/interleukin-17 axis links adaptive and innate immunity in psoriasis","volume":"9","author":"Schon","year":"2018","journal-title":"Front Immunol"},{"key":"2021042318143730000_cvaa257-B19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cyto.2013.07.022","article-title":"IL-17 family: cytokines, receptors and signaling","volume":"64","author":"Gu","year":"2013","journal-title":"Cytokine"},{"key":"2021042318143730000_cvaa257-B20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.immuni.2004.08.018","article-title":"Interleukin-17 family members and inflammation","volume":"21","author":"Kolls","year":"2004","journal-title":"Immunity"},{"key":"2021042318143730000_cvaa257-B21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3892\/etm.2015.2939","article-title":"IL-17 promotes keratinocyte proliferation via the downregulation of C\/EBPalpha","volume":"11","author":"Ma","year":"2016","journal-title":"Exp Ther Med"},{"key":"2021042318143730000_cvaa257-B22","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.3748\/wjg.v21.i19.5823","article-title":"Contribution of the IL-17\/IL-23 axis to the pathogenesis of inflammatory bowel disease","volume":"21","author":"C\u0103tan\u0103","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2021042318143730000_cvaa257-B23","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/cvr\/cvs422","article-title":"Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension","volume":"97","author":"Nguyen","year":"2013","journal-title":"Cardiovasc Res"},{"key":"2021042318143730000_cvaa257-B24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/intimm\/dxs056","article-title":"IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKCbeta\/Erk1\/2\/NF-kappaB-dependent signaling pathway","volume":"24","author":"Liu","year":"2012","journal-title":"Int Immunol"},{"key":"2021042318143730000_cvaa257-B25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.yjmcc.2018.08.005","article-title":"Interleukin-17 enhances cardiac ventricular remodeling via activating MAPK pathway in ischemic heart failure","volume":"122","author":"Chang","year":"2018","journal-title":"J Mol Cell Cardiol"},{"key":"2021042318143730000_cvaa257-B26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.yjmcc.2018.01.001","article-title":"Ablation of interleukin-17 alleviated cardiac interstitial fibrosis and improved cardiac function via inhibiting long non-coding RNA-AK081284 in diabetic mice","volume":"115","author":"Zhang","year":"2018","journal-title":"J Mol Cell Cardiol"},{"key":"2021042318143730000_cvaa257-B27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cyto.2017.10.015","article-title":"Role of interleukin 17 in TGF-beta signaling-mediated renal interstitial fibrosis","volume":"106","author":"Sun","year":"2018","journal-title":"Cytokine"},{"key":"2021042318143730000_cvaa257-B28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.109.145094","article-title":"Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction","volume":"55","author":"Madhur","year":"2010","journal-title":"Hypertension"},{"key":"2021042318143730000_cvaa257-B29","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jacbts.2016.07.009","article-title":"Inhibition of interleukin 17-A but not interleukin-17F signaling lowers blood pressure and reduces end-organ inflammation in angiotensin II-induced hypertension","volume":"1","author":"Saleh","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"2021042318143730000_cvaa257-B30","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1161\/ATVBAHA.114.304108","article-title":"Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease","volume":"34","author":"Karbach","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2021042318143730000_cvaa257-B31","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jid.2018.09.021","article-title":"Antagonization of IL-17A attenuates skin inflammation and vascular dysfunction in mouse models of psoriasis","volume":"139","author":"Schuler","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2021042318143730000_cvaa257-B32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/CS20190682","article-title":"Interleukin-17A induces vascular remodeling of small arteries and blood pressure elevation","volume":"134","author":"Orejudo","year":"2020","journal-title":"Clin Sci (Lond)"},{"key":"2021042318143730000_cvaa257-B33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1161\/HYPERTENSIONAHA.116.07493","article-title":"Interleukin-17A regulates renal sodium transporters and renal injury in angiotensin II-induced hypertension","volume":"68","author":"Norlander","year":"2016","journal-title":"Hypertension"},{"key":"2021042318143730000_cvaa257-B34","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.113.02883","article-title":"Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes","volume":"63","author":"Amador","year":"2014","journal-title":"Hypertension"},{"key":"2021042318143730000_cvaa257-B35","doi-asserted-by":"crossref","first-page":"e92801","DOI":"10.1172\/jci.insight.92801","article-title":"A salt-sensing kinase in T lymphocytes, SGK1, drives hypertension and hypertensive end-organ damage","volume":"2","author":"Norlander","year":"2017","journal-title":"JCI Insight"},{"key":"2021042318143730000_cvaa257-B36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/path.4430","article-title":"IL-17A produced by both gammadelta T and Th17 cells promotes renal fibrosis via RANTES-mediated leukocyte infiltration after renal obstruction","volume":"235","author":"Peng","year":"2015","journal-title":"J Pathol"},{"key":"2021042318143730000_cvaa257-B37","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.ajpath.2016.07.015","article-title":"C motif chemokine 5 attenuates angiotensin II-dependent kidney injury by limiting renal macrophage infiltration","volume":"186","author":"Rudemiller","year":"2016","journal-title":"Am J Pathol"},{"key":"2021042318143730000_cvaa257-B38","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/jch.12612","article-title":"Elevated serum level of interleukin 17 in a population with prehypertension","volume":"17","author":"Yao","year":"2015","journal-title":"J Clin Hypertens"},{"key":"2021042318143730000_cvaa257-B39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1471-2369-15-159","article-title":"The relationship between asymptomatic organ damage, and serum soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and Interleukin-17A (IL-17A) levels in non-diabetic hypertensive patients","volume":"15","author":"Ates","year":"2014","journal-title":"BMC Nephrol"},{"key":"2021042318143730000_cvaa257-B40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1161\/HYPERTENSIONAHA.116.07237","article-title":"Activation of human T cells in hypertension: studies of humanized mice and hypertensive humans","volume":"68","author":"Itani","year":"2016","journal-title":"Hypertension"},{"key":"2021042318143730000_cvaa257-B41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000471900","article-title":"Interleukin 17A and toll-like receptor 4 in patients with arterial hypertension","volume":"42","author":"Simundic","year":"2017","journal-title":"Kidney Blood Press Res"},{"key":"2021042318143730000_cvaa257-B42","doi-asserted-by":"crossref","first-page":"R353","DOI":"10.1152\/ajpregu.00051.2012","article-title":"IL-17-mediated oxidative stress is an important stimulator of AT1-AA and hypertension during pregnancy","volume":"303","author":"Dhillion","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2021042318143730000_cvaa257-B43","doi-asserted-by":"crossref","DOI":"10.1093\/ajh\/hpaa103","article-title":"Microbiota and hypertension: role of the sympathetic nervous system and the immune system","author":"Robles-Vera","year":"2020","journal-title":"Am J Hypertens"},{"key":"2021042318143730000_cvaa257-B44","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nature24628","article-title":"Salt-responsive gut commensal modulates TH17 axis and disease","volume":"551","author":"Wilck","year":"2017","journal-title":"Nature"},{"key":"2021042318143730000_cvaa257-B45","doi-asserted-by":"crossref","first-page":"e13285","DOI":"10.1111\/apha.13285","article-title":"Role of the immune system in vascular function and blood pressure control induced by faecal microbiota transplantation in rats","volume":"227","author":"Toral","year":"2019","journal-title":"Acta Physiol"},{"key":"2021042318143730000_cvaa257-B46","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/cvr\/cvw172","article-title":"The angiotensin II type 2 receptor activates flow-mediated outward remodelling through T cells-dependent interleukin-17 production","volume":"112","author":"Caillon","year":"2016","journal-title":"Cardiovasc Res"},{"key":"2021042318143730000_cvaa257-B47","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1681\/ASN.2014111136","article-title":"Low-dose IL-17 therapy prevents and reverses diabetic nephropathy, metabolic syndrome, and associated organ fibrosis","volume":"27","author":"Mohamed","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2021042318143730000_cvaa257-B48","first-page":"369","article-title":"Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis","volume":"22","author":"Yoshiga","year":"2008","journal-title":"Int J Mol Med"},{"key":"2021042318143730000_cvaa257-B49","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/jid.2013.526","article-title":"In vivo induction of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing RORgammat and IL-17","volume":"134","author":"Keijsers","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2021042318143730000_cvaa257-B50","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1111\/bjd.15533","article-title":"Interleukin (IL)-17A and IL-22-producing neutrophils in psoriatic skin","volume":"177","author":"Dyring-Andersen","year":"2017","journal-title":"Br J Dermatol"},{"key":"2021042318143730000_cvaa257-B51","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/imm.12862","article-title":"Dissecting human ILC heterogeneity: more than just three subsets","volume":"153","author":"Simoni","year":"2018","journal-title":"Immunology"},{"key":"2021042318143730000_cvaa257-B52","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/ni.3726","article-title":"17(+) gammadelta T cells as kick-starters of inflammation","volume":"18","author":"Papotto","year":"2017","journal-title":"Nat Immunol"},{"key":"2021042318143730000_cvaa257-B53","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fimmu.2015.00118","article-title":"A highly focused antigen receptor repertoire characterizes gammadelta T cells that are poised to make IL-17 rapidly in naive animals","volume":"6","author":"Wei","year":"2015","journal-title":"Front Immunol"},{"key":"2021042318143730000_cvaa257-B54","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/CIRCULATIONAHA.116.027058","article-title":"gammadelta T cells mediate angiotensin II-induced hypertension and vascular injury","volume":"135","author":"Caillon","year":"2017","journal-title":"Circulation"},{"key":"2021042318143730000_cvaa257-B55","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/infdis\/jiw443","article-title":"Two types of interleukin 17A-producing gammadelta T cells in protection against pulmonary infection with Klebsiella pneumoniae","volume":"214","author":"Murakami","year":"2016","journal-title":"J Infect Dis"},{"key":"2021042318143730000_cvaa257-B56","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/jir.2010.0083","article-title":"Interleukin-23-induced interleukin-23 receptor subunit expression is mediated by the Janus kinase\/signal transducer and activation of transcription pathway in human CD4 T cells","volume":"31","author":"Che Mat","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"2021042318143730000_cvaa257-B57","doi-asserted-by":"crossref","first-page":"e48647","DOI":"10.15252\/embr.201948647","article-title":"STAT3 but not STAT4 is critical for gammadeltaT17 cell responses and skin inflammation","volume":"20","author":"Agerholm","year":"2019","journal-title":"EMBO Rep"},{"key":"2021042318143730000_cvaa257-B58","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00014-17","article-title":"Synthetic deletion of the interleukin 23 receptor (IL-23R) stalk region led to autonomous IL-23R homodimerization and activation","volume":"37","author":"Hummel","year":"2017","journal-title":"Mol Cell Biol"},{"key":"2021042318143730000_cvaa257-B59","doi-asserted-by":"crossref","first-page":"e3000646","DOI":"10.1371\/journal.pbio.3000646","article-title":"IL-23 signaling regulation of pro-inflammatory T-cell migration uncovered by phosphoproteomics","volume":"18","author":"\u00c1lvarez-Salamero","year":"2020","journal-title":"PLoS Biol"},{"key":"2021042318143730000_cvaa257-B60","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/jir.2018.0006","article-title":"Interleukin-23: a new atherosclerosis target","volume":"38","author":"Liu","year":"2018","journal-title":"J Interferon Cytokine Res"},{"key":"2021042318143730000_cvaa257-B61","first-page":"1","article-title":"The expression of IL-12 family members in patients with hypertension and its association with the occurrence of carotid atherosclerosis","volume":"2020","author":"Ye","year":"2020","journal-title":"Mediators Inflamm"},{"key":"2021042318143730000_cvaa257-B62","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13098-016-0164-2","article-title":"Association of cardiac NT pro-beta-type natriuretic peptide with metabolic and endothelial risk factors in young obese hypertensive patients: a perspective on the hypothalamic pituitary adrenal axis activation","volume":"8","author":"Schaalan","year":"2016","journal-title":"Diabetol Metab Syndr"},{"key":"2021042318143730000_cvaa257-B63","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nature11984","article-title":"Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1","volume":"496","author":"Wu","year":"2013","journal-title":"Nature"},{"key":"2021042318143730000_cvaa257-B64","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/dna.2014.2573","article-title":"Functional polymorphisms in interleukin-23 receptor and susceptibility to coronary artery disease","volume":"33","author":"Zhang","year":"2014","journal-title":"DNA Cell Biol"},{"key":"2021042318143730000_cvaa257-B65","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.4049\/jimmunol.1300626","article-title":"IL-23 receptor expression on gammadelta T cells correlates with their enhancing or suppressive effects on autoreactive T cells in experimental autoimmune uveitis","volume":"191","author":"Liang","year":"2013","journal-title":"J Immunol"},{"key":"2021042318143730000_cvaa257-B66","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/imm.12946","article-title":"Interleukin-23 promotes intestinal T helper type17 immunity and ameliorates obesity-associated metabolic syndrome in a murine high-fat diet model","volume":"154","author":"Martins","year":"2018","journal-title":"Immunology"},{"key":"2021042318143730000_cvaa257-B67","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.immuni.2018.09.011","article-title":"An interleukin-23-interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis","volume":"49","author":"Fatkhullina","year":"2018","journal-title":"Immunity"},{"key":"2021042318143730000_cvaa257-B68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molimm.2012.02.004","article-title":"Distinct MAPK pathways are involved in IL-23 production in dendritic cells cocultured with NK cells in the absence or presence of angiotensin II","volume":"51","author":"Yang","year":"2012","journal-title":"Mol Immunol"},{"key":"2021042318143730000_cvaa257-B69","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.celrep.2017.12.068","article-title":"SGK1 governs the reciprocal development of Th17 and regulatory T cells","volume":"22","author":"Wu","year":"2018","journal-title":"Cell Rep"},{"key":"2021042318143730000_cvaa257-B70","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1161\/HYPERTENSIONAHA.117.09063","article-title":"Loss of resistance to angiotensin II-induced hypertension in the Jackson laboratory recombination-activating gene null mouse on the C57BL\/6J background","volume":"69","author":"Ji","year":"2017","journal-title":"Hypertension"},{"key":"2021042318143730000_cvaa257-B71","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1161\/HYPERTENSIONAHA.119.13773","article-title":"B6.Rag1 knockout mice generated at the Jackson laboratory in 2009 show a robust wild-type hypertensive phenotype in response to Ang II (angiotensin II)","volume":"75","author":"Seniuk","year":"2020","journal-title":"Hypertension"},{"key":"2021042318143730000_cvaa257-B72","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2021042318143730000_cvaa257-B73","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.119.13642","article-title":"Effects of interleukin-1beta inhibition on blood pressure, incident hypertension, and residual inflammatory risk: a secondary analysis of CANTOS","volume":"75","author":"Rothman","year":"2020","journal-title":"Hypertension"},{"key":"2021042318143730000_cvaa257-B74","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1161\/HYPERTENSIONAHA.119.13982","article-title":"IL (interleukin)-1 receptor antagonist increases Ang (angiotensin [1-7]) and decreases blood pressure in obese individuals","volume":"75","author":"Urwyler","year":"2020","journal-title":"Hypertension"},{"key":"2021042318143730000_cvaa257-B75","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/ATVBAHA.119.311998","article-title":"Anticytokine immune therapy and atherothrombotic cardiovascular risk","volume":"39","author":"Ait-Oufella","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2021042318143730000_cvaa257-B76","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1468-3083.2012.04500.x","article-title":"Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12\/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials","volume":"27","author":"Tzellos","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021042318143730000_cvaa257-B77","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2567.2005.02257.x","article-title":"The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects","volume":"117","author":"Shimozato","year":"2006","journal-title":"Immunology"},{"key":"2021042318143730000_cvaa257-B78","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/jdv.12126","article-title":"Association of anti-IL-12\/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events","volume":"27","author":"Tzellos","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021042318143730000_cvaa257-B79","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2021042318143730000_cvaa257-B80","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"2021042318143730000_cvaa257-B81","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"2021042318143730000_cvaa257-B82","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/bjd.17628","article-title":"Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study","volume":"181","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"key":"2021042318143730000_cvaa257-B83","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"von Stebut","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2021042318143730000_cvaa257-B84","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2018.02.074","article-title":"Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: results from UNCOVER-1, UNCOVER-2, and UNCOVER-3","volume":"79","author":"Egeberg","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2021042318143730000_cvaa257-B85","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40259-019-00361-6","article-title":"Bimekizumab: the first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitis","volume":"33","author":"Reis","year":"2019","journal-title":"BioDrugs"},{"key":"2021042318143730000_cvaa257-B86","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2021042318143730000_cvaa257-B87","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"2021042318143730000_cvaa257-B88","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1161\/HYPERTENSIONAHA.111.183178","article-title":"Roles of interleukin 17 in angiotensin II type 1 receptor-mediated insulin resistance","volume":"59","author":"Ohshima","year":"2012","journal-title":"Hypertension"},{"key":"2021042318143730000_cvaa257-B89","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.21873\/invivo.11386","article-title":"Blocking of type 1 angiotensin II receptor inhibits T-lymphocyte activation and IL-2 production","volume":"32","author":"Tawinwung","year":"2018","journal-title":"In Vivo"},{"key":"2021042318143730000_cvaa257-B90","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1161\/ATVBAHA.111.237198","article-title":"Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis","volume":"31","author":"Yamamoto","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvaa257\/34160684\/cvaa257.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/117\/5\/1274\/37313657\/cvaa257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/117\/5\/1274\/37313657\/cvaa257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T14:33:19Z","timestamp":1619188399000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/117\/5\/1274\/5900262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":90,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,9,1]]},"published-print":{"date-parts":[[2021,4,23]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvaa257","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2020,9,1]]}}}